Additionally, we noticed that the combined regimen dramatically downregulated the levels of VEGFR and its phosphorylated form (p-VEGFR) in CD34+CD38−KG1α and primary CD34+ AML cells (Fig. 6C). This evidence concerns the gene CD34 and acute myeloid leukemia.